<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00870415</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633327</org_study_id>
    <secondary_id>CLCC-PHRC-OP-06</secondary_id>
    <secondary_id>CLCC-VA-2006/32</secondary_id>
    <secondary_id>CLCC-ID-RCB-2006-A00694-47</secondary_id>
    <secondary_id>INCA-RECF0638</secondary_id>
    <nct_id>NCT00870415</nct_id>
  </id_info>
  <brief_title>Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer</brief_title>
  <official_title>Multicenter (Phase II) Study of Oncoplastic Surgical Techniques for Breast Conservation in Breast Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <brief_summary>
    <textblock>
      RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and
      may have fewer side effects and improve recovery.

      PURPOSE: This phase II trial is studying different breast-conserving surgery techniques in
      treating women with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the percentage of histologically healthy margins maintained during resection in
           women with breast cancer.

      Secondary

        -  Evaluate local recurrence at 5 years.

        -  Evaluate aesthetic results.

        -  Evaluate quality of life using the QLQC30 and BR23 questionnaires.

      OUTLINE: This is a multicenter study.

      Patients undergo oncoplastic conservative surgery according to defined modalities across the
      various centers.

      Quality of life is assessed periodically.

      After completion of study treatment, patients are followed every 6 months for 2 years and
      then for at least 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of histologically healthy margins maintained during resection</measure>
    <time_frame>From inclusion to end of intervention</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Surgerie</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Surgerie</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Surgerie</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Diagnosis of intraductal breast cancer requiring a wide local resection

               -  Diagnosis of infiltrating ductal breast cancer within range

               -  Diagnosis of invasive breast cancer that has not responded well to neoadjuvant
                  treatment

          -  No multicentric tumor

          -  No gigantomastia

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  No patients subject to a measure of legal protection or unable to express consent

          -  No patients deprived of liberty by judicial or administrative decision or hospitalized
             without patient consent

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy to the diseased breast

          -  No prior adjuvant treatment

          -  No concurrent participation in another clinical research study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Rouanet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2009</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>ductal breast carcinoma</keyword>
  <keyword>invasive ductal breast carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

